Suven Pharma, owned by Advent International, is pursuing mergers and acquisitions to enhance its technological capabilities and expand its order book. The company has announced plans to acquire a majority stake in NJ Bio for $64 million. This acquisition is part of a broader strategy by Advent International to implement significant changes at Suven Pharma, including a management overhaul. Additionally, Suven Pharma plans to open 600 retail stores by FY2026, indicating a robust growth trajectory. Analysts have issued a 'buy' recommendation for the company, suggesting confidence in its future performance.